RDY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dr. Reddy's Laboratories Ltd (RDY) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are bearish, options data suggests weak sentiment, analysts have downgraded the stock, and there are no strong positive catalysts to counteract these factors.
The MACD histogram is negative and contracting, RSI is neutral at 50.192, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Support and resistance levels suggest limited upward momentum with key resistance at 13.428 and support at 13.13.
Dr. Reddy's recently launched Bosutinib Tablets 400mg in the U.S., expanding its oncology portfolio.
Goldman Sachs and Citi analysts downgraded the stock, citing limited pipeline opportunities and intensified competition for generic Ozempic in Canada. Stock trend analysis predicts a decline of -0.42% in the next day, -3.13% in the next week, and -7.78% in the next month.
No financial data available for analysis.
Goldman Sachs downgraded the stock to Sell with a price target of INR 1,075, citing limited pipeline opportunities and intensified competition. Citi reiterated a Sell rating, noting that the market for generic semaglutide in Canada will have six players, limiting upside potential.
